Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02371941 · ClinicalTrials.gov registry record · Phase 4

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

A Phase 4 study of Eosinophilic Esophagitis, sponsored by University of Tennessee.

Completed
Registry status
Phase 4
Development phase
16
Enrollment target
1
Study location

NCT02371941: Completed Phase 4 study of Eosinophilic Esophagitis, sponsored by University of Tennessee.

NCT02371941 is a Phase 4 study of Eosinophilic Esophagitis that has completed, run by University of Tennessee. The registered enrollment target is 16 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02371941, a Phase 4 study of Eosinophilic Esophagitis, has completed, sponsored by University of Tennessee.

COMPLETED
Registry status
Phase 4
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, double-blind, placebo-controlled study of oral cromolyn sodium when made into a viscous preparation for the treatment of eosinophilic esophagitis.

Primary Outcome

Measure of the peak esophageal eosinophil count on esophageal biopsy specimens after 2 months of therapy

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG oral cromolyn sodium

Study Locations (1)

Tennessee

  • LeBonheur Children's Hospital - Memphis

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2014-12
Est. Completion 2017-12
Phase Phase 4
University of Tennessee

96 total trials

What the finished NCT02371941 record still lists

NCT02371941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02371941 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT02371941 about?

NCT02371941 is a clinical study titled "Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis". This is a randomized, double-blind, placebo-controlled study of oral cromolyn sodium when made into a viscous preparation for the treatment of eosinophilic esophagitis.

What is the current status of trial NCT02371941?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2014-12. Estimated completion is 2017-12.

What conditions does trial NCT02371941 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis.

What interventions are being tested in trial NCT02371941?

The interventions under investigation include: Placebo (DRUG), oral cromolyn sodium (DRUG).

Who is sponsoring clinical trial NCT02371941?

This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02371941 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eosinophilic Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02371941's enrollment target sits among peer trials

16 40th of 44 higher than 4 of 44 other Eosinophilic Esophagitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02371941, the US trial registry maintained by the National Library of Medicine. NCT02371941 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.